PTC Therapeutics Inc's stock fell by 5.85%, crossing down the 5-day SMA amid recent insider selling activities. Emma Reeve, an independent board director, sold 10,000 shares for approximately $795,000, reducing her holdings significantly.
The company has faced challenges with revenue growth, reporting a 7% year-over-year increase to $211 million in the third quarter, while sales of its muscular dystrophy treatment, Translarna, have declined. This insider selling may indicate a lack of confidence in the company's near-term performance.
Additionally, the broader market context shows the Nasdaq-100 (QQQ) down 0.06% and the S&P 500 (SPY) down 0.08%, suggesting a cautious sentiment among investors that could be impacting PTC Therapeutics Inc's stock performance.
Wall Street analysts forecast PTCT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PTCT is 78.18 USD with a low forecast of 54.00 USD and a high forecast of 118.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
14 Analyst Rating
Wall Street analysts forecast PTCT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PTCT is 78.18 USD with a low forecast of 54.00 USD and a high forecast of 118.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Buy
5 Hold
1 Sell
Moderate Buy
Current: 75.600
Low
54.00
Averages
78.18
High
118.00
Current: 75.600
Low
54.00
Averages
78.18
High
118.00
Barclays
Equal Weight -> Overweight
upgrade
$68 -> $119
2026-01-27
New
Reason
Barclays
Price Target
$68 -> $119
AI Analysis
2026-01-27
New
upgrade
Equal Weight -> Overweight
Reason
Barclays upgraded PTC Therapeutics to Overweight from Equal Weight with a price target of $119, up from $68, after assuming coverage of the name. Barclays initiated coverage of 12 biotech stocks and assumed coverage of 11 with a positive view of the industry. The analyst likes the setup for the group in 2026. Many biotech stocks remain undervalued, the analyst tells investors in a research note. The firm expects continued mergers and acquisitions, "strong" underlying fundamentals, and less of a focus on drug pricing to act as "significant tailwinds." Barclays thinks phenylketonuria could be an over $2B sales opportunity for PTC. This is underappreciated in the shares, the firm contends.
Morgan Stanley
Overweight
maintain
$78 -> $90
2026-01-08
Reason
Morgan Stanley
Price Target
$78 -> $90
2026-01-08
maintain
Overweight
Reason
Morgan Stanley raised the firm's price target on PTC Therapeutics to $90 from $78 and keeps an Overweight rating on the shares. The firm sees a continuation of U.S. small-to-mid cap biotech's outperformance in 2026 as commercial names transition from "capital consumers to producers" and Large Cap Biopharma faces a looming patent cliff, the analyst tells investors in an outlook note for the group.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for PTCT
Unlock Now
Goldman Sachs
NULL -> Sell
downgrade
$44 -> $50
2025-11-06
Reason
Goldman Sachs
Price Target
$44 -> $50
2025-11-06
downgrade
NULL -> Sell
Reason
Goldman Sachs raised the firm's price target on PTC Therapeutics to $50 from $44 and keeps a Sell rating on the shares.
Goldman Sachs
Sell
maintain
$44 -> $50
2025-11-05
Reason
Goldman Sachs
Price Target
$44 -> $50
2025-11-05
maintain
Sell
Reason
Goldman Sachs raised the firm's price target on PTC Therapeutics to $50 from $44 and keeps a Sell rating on the shares. PTC Therapeutics reported stronger-than-expected Q3 results driven by robust early Sephience sales and solid performance from the legacy Duchenne muscular dystrophy franchise, the analyst tells investors in a research note. Sephience's launch showed encouraging momentum with broad COE engagement and favorable early payer dynamics, though DMD revenue continued to decline sequentially. While early uptake supports confidence in Sephience's trajectory, U.S. sales targets above $1B appear ambitious, and attention now turns to ongoing launch progress, the upcoming votoplam FDA update, and pipeline developments at December's R&D day, Goldman says.
About PTCT
PTC Therapeutics, Inc. is a global biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. It has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD) a rare, life-threatening disorder. Its Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, a rare central nervous system (CNS) disorder. Its Tegsedi and Waylivra are for the treatment of rare diseases. Its Evrysdi, a treatment for spinal muscular atrophy (SMA).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
